Adaptive Biotechnologies launched an enhanced version of its clonoSEQ® B-cell Clonality report. It will now feature the immunoglobulin heavy chain variable gene mutation status for patients with chronic lymphocytic leukemia (CLL).
The clonoSEQ assay was approved by the U.S. Food and Drug Administration to detect and monitor minimal residual disease in the blood or bone marrow of patients with CLL.
For more information on the clonoSEQ assay and its enhancements, read the Adaptive Biotechnologies announcement.
Posted 10/19/2021
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
